Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus‐related hepatocellular carcinoma

Kuzuya, Teiji; Katano, Yoshiaki; Kumada, Takashi; Toyoda, Hidenori; Nakano, Isao; Hirooka, Yoshiki; Itoh, Akihiro; Ishigami, Masatoshi; Hayashi, Kazuhiko; Honda, Takashi; Goto, Hidemi

doi:10.1111/j.1440-1746.2006.04707.x

Cited by 118 publications

(152 citation statements)

References 25 publications

Supporting

Mentioning

144

Contrasting

Order By: Relevance

“…The cumulative HCC recurrence rate of the patients treated with IFN-alfa and the control group was 25 and 40% at the end of 1 year and 47 and 90% at the end of 4 years, respectively (P = 0.0135). Furthermore, this study also showed that the prevention of HCC recurrence using IFN-alfa was effective in HBV-related HCC [392] Lamivudine A retrospective study was conducted to evaluate the efficacy with or without using LAM in patients following curative ablation of HBV-related HCC [393]. Cumulative recurrence rates of HCC were not significantly different between two groups (P = 0.622).…”

Section: Tertiary Prevention For Hbv-related Hccmentioning

confidence: 98%

“…However, median C-P score at the time of HCC recurrence was significantly different in the control group (P = 0.005). The cumulative survival rates of patients in the LAM group tended to be higher than those of patients in the control group (P = 0.063) [393]. The outcome of LAM treatment of patients with controlled HCC in terms C-P score and survival compared with a matched, LAM-untreated cohort showed no significant difference in the cumulative incidence of HCC recurrence and survival between the two groups [394].…”

Section: Tertiary Prevention For Hbv-related Hccmentioning

confidence: 99%

See 1 more Smart Citation

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Introduction The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. 123Hepatol Int (2010) 4: 439-474 DOI 10.1007/s12072-010-9165-7 Results Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

show abstract

Section: Tertiary Prevention For Hbv-related Hccmentioning

confidence: 98%

Section: Tertiary Prevention For Hbv-related Hccmentioning

confidence: 99%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Several retrospective studies [21][22][23][26][27][28][29]33,35] showed that NA treatment did not lead to significantly higher recurrence-free survival than non-NA treatment, while other retrospective studies [24,25,[30][31][32]34,36,37] and the RCTs [38,39] showed that NA therapy was associated with significantly higher recurrence-free survival than non-NA treatment.…”

Section: Recurrence-free Survivalmentioning

confidence: 99%

“…These references comprise 17 retrospective studies [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] and 2 RCTs [38,39] . Most of studies come from Asia, including Chinese mainland, Japan, Hong Kong and Tai Wan, which reflects HBV epidemiology and the high incidence of HBV-related HCC in this region.…”

Section: Recurrence-free Survivalmentioning

confidence: 99%

Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection

Yang

Wang

et al. 2014

WJH

View full text Add to dashboard Cite

Significant advances have been made in nucleos(t)ide analogue (NA) therapy to treat chronic hepatitis B, and this therapy reduces the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in some patients. However, whether NAs can also prevent recurrence after radical resection of HBV-related HCC remains controversial and is an important question, given that most patients will experience recurrence within a few years of curative surgery. Here we systematically reviewed the literature since 2004 on outcomes after administering NAs to patients with HBV-related HCC following radical resection. We focused on treatment indications, duration, effects on recurrence-free survival and overall survival, and the management of NA resistance. We find that patients with HCC should strongly consider NA therapy if they are positive for HBV-DNA, and that the available evidence suggests that postoperative NA therapy can increase both recurrence-free and overall survival. To minimize drug resistance, clinicians should opt for potent analogues with higher resistance barriers, and they should monitor the patient carefully for emergence of NA-resistant HBV.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Antiviral therapy; Hepatitis B virus; Hepatocellular carcinoma; Liver resection; Nucleos(t)ide analogue; Survival rate Core tip: Significant advances have been made in nucleos(t)ide analogue (NA) therapy to treat chronic hepatitis B. However, for patients undergoing radical resection for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), a number of important questions remain undefined, including when NA therapy should be initiated, how long the treatment should continue, and whether NAs can prevent recurrence after radical resection. Here we review the available evidence on these questions in the Medline database. We focus on NA treatment indications, duration, effects on recurrencefree survival and overall survival, and management of NA resistance in patients with HBV-related HCC.Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol 2014; 6(9): 652-659 Available from:

show abstract

“…In recent years, several reports from Japan have shown improved survival with lamivudine (LAM) therapy in patients following local treatment of HCC. [5][6][7][8] We report the effect of antiviral therapy on long-term survival (some patients approaching >10 years) of CHB patients whose initial HCC is locally ablated. This study was approved by the Institutional Review Board of Thomas Jefferson University.…”

Section: Dear Editormentioning

confidence: 99%

Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated

Hann¹,

Bergin²,

Coben³

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus‐related hepatocellular carcinoma

Cited by 118 publications

References 25 publications

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection

Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated

Contact Info

Product

Resources

About